Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 645

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Attal, Michel, Richardson, Paul G, Rajkumar, S Vincent, San-Miguel, Jesus, Beksac, Meral, Spicka, Ivan, Leleu, Xavier, Schjesvold, Fredrik, Moreau, Philippe, Dimopoulos, Meletios A, Huang, Jeffrey Shang-Yi, Minarik, Jiri, Cavo, Michele, Prince, H Miles, Macé, Sandrine, Corzo, Kathryn P, Campana, Frank, Le-Guennec, Solenn, Dubin, Franck, Anderson, Kenneth C, Attal, Michel, Richardson, Paul G., Rajkumar, Vincent, San-Miguel, Jesus, Beksac, Meral, Spicka, Ivan, Leleu, Xavier, Schjesvold, Fredrik, Moreau, Philippe, Dimopoulos, Meletios A., Huang, Jeffrey Shang-Yi, Minarik, Jiri, Cavo, Michele, Prince, H. Miles, Macé, Sandrine, Corzo, Kathryn P., Campana, Frank, Le-Guennec, Solenn, Dubin, Franck, Anderson, Kenneth C., Harrison, Simon, Janowski, Wojt, Kerridge, Ian, Spencer, Andrew, Delforge, Michel, Fostier, Karel, Vlummens, Philip, Wu, Ka Lung, Leblanc, Richard, Pavic, Michel, Sebag, Michael, Hajek, Roman, Maisnar, Vladimir, Pour, Ludek, Gregersen, Henrik, Benbouker, Lotfi, Caillot, Denis, Escoffre-Barbe, Martine, Facon, Thierry, Frenzel, Laurent, Hulin, Cyrille, Karlin, Lionel, Kolb, Brigitte, Pegourie, Brigitte, Perrot, Aurore, Tiab, Mourad, Vincent, Laure, Niederwieser, Dietger, Anagnostopoulos, Achilles, Delimpasi, Sosana, Kyrtsonis, Marie-Christine, Symeonidis, Anargyros, Illes, Arpad, Mikala, Gabor, Nagy, Zsolt, Bringen, Sara, Corradini, Paolo, Fabio, Ciceri, Lemoli, Roberto, Liberati, Anna, Nozzoli, Chiara, Zambello, Renato, Iida, Shinsuke, Ikeda, Takashi, Iyama, Satoshi, Matsumoto, Morio, Shimazaki, Chihiro, Sunami, Kazutaka, Suzuki, Kenshi, Uchiyama, Michihiro, Koh, Youngil, Kim, Kihyun, Lee, Jae Hoon, Min, Chang-Ki, Blacklock, Hillary, Goodman, Hugh, Neylon, Annette, Simpson, David, Grosicki, Sebastian, Jurczyszyn, Artur, Walter-Croneck, Adam, Warzocha, Krzysztof, Araujo, Luis, Moreira, Claudia, Doronin, Vadim, Mendeleeva, Larisa, Vorobyev, Vladimir, Vranovsky, Andrej, Alegre, Adrian, Gironella, Mercedes, Gonzalez Perez, Marta Sonia, Montes, Carmen, Ocio, Enrique, Rodriguez, Paula, Hardling, Mats, Lauri, Birgitta, Wang, Ming-Chung, Yeh, Su-Peng, Arat, Mutlu, Demirkan, Fatih, Gulbas, Zafer, Besisik, Sevgi Kalayoglu, Karadogan, Ihsan, Tuglular, Tulin, Unal, Ali, Vural, Filiz, Sive, Jonathan, Streetly, Matthew, Yong, Kwee, Tache, Jason · 2019 · The Lancet

Abstract

BACKGROUND Isatuximab is a monoclonal antibody that binds a specific epitope on the human CD38 receptor and has antitumour activity via multiple mechanisms of action. In a previous phase 1b study, around 65% of patients with relapsed and refractory multiple myeloma achieved an overall response with a combination of isatuximab with pomalidomide and low-dose dexamethasone. The aim of this study was to determine the progression-free survival benefit of isatuximab plus pomalidomide and dexamethasone compared with pomalidomide and dexamethasone in patients with relapsed and refractory multiple myeloma. METHODS We did a randomised, multicentre, open-label, phase 3 study at 102 hospitals in 24 countries in Europe, North America, and the Asia-Pacific regions. Eligible participants were adult patients with relapsed and refractory multiple myeloma who had received at least two previous lines of treatment, including lenalidomide and a proteasome inhibitor. Patients were excluded if they were refractory to previous treatment with an anti-CD38 monoclonal antibody. We randomly assigned patients (1:1) to either isatuximab 10 mg/kg plus pomalidomide 4 mg plus dexamethasone 40 mg (20 mg for patients aged ≥75 years), or pomalidomide 4 mg plus dexamethasone 40 mg. Randomisation was done using interactive response technology and stratified according to the number of previous lines of treatment (2-3 vs >3) and age (<75 years vs ≥75 years). Treatments were assigned based on a permuted blocked randomisation scheme with a block size of four. The isatuximab-pomalidomide-dexamethasone group received isatuximab intravenously on days 1, 8, 15, and 22 in the first 28-day cycle, then on days 1 and 15 in subsequent cycles. Both groups received oral pomalidomide on days 1 to 21 in each cycle, and oral or intravenous dexamethasone on days 1, 8, 15, and 22 of each cycle. Treatment continued until disease progression, unacceptable toxicity, or consent withdrawal. Dose reductions for adverse reactions were permitted for pomalidomide and dexamethasone, but not for isatuximab. The primary endpoint was progression-free survival, determined by an independent response committee and assessed in the intention-to-treat population. Safety was assessed in all participants who received at least one dose of study drug. This study is registered at ClinicalTrials.gov, number NCT02990338. FINDINGS Between Jan 10, 2017, and Feb 2, 2018, we randomly assigned 307 patients to treatment: 154 to isatuximab-pomalidomide-dexamethasone, and 153 to pomalidomide-dexamethasone. At a median follow-up of 11·6 months (IQR 10·1-13·9), median progression-free survival was 11·5 months (95% CI 8·9-13·9) in the isatuximab-pomalidomide-dexamethasone group versus 6·5 months (4·5-8·3) in the pomalidomide-dexamethasone group; hazard ratio 0·596, 95% CI 0·44-0·81; p=0·001 by stratified log-rank test. The most frequent treatment-emergent adverse events (any grade; isatuximab-pomalidomide-dexamethasone vs pomalidomide-dexamethasone) were infusion reactions (56 [38%] vs 0), upper respiratory tract infections (43 [28%] vs 26 [17%]), and diarrhoea (39 [26%] vs 29 [20%]). Adverse events with a fatal outcome were reported in 12 patients (8%) in the isatuximab-pomalidomide-dexamethasone group and 14 (9%) in the pomalidomide-dexamethasone group. Deaths due to treatment-related adverse events were reported for one patient (<1%) in the isatuximab-pomalidomide-dexamethasone group (sepsis) and two (1%) in the pomalidomide-dexamethasone group (pneumonia and urinary tract infection). INTERPRETATION The addition of isatuximab to pomalidomide-dexamethasone significantly improves progression-free survival in patients with relapsed and refractory multiple myeloma. Isatuximab is an important new treatment option for the management of relapsed and refractory myeloma, particularly for patients who become refractory to lenalidomide and a proteasome inhibitor. FUNDING Sanofi. VIDEO ABSTRACT.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(19)32556-5

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 31 references

Research works printed but not linked: 2

  1. Cai, 2013, Preclinical characterisation of SAR650984, a humanized anti-CD38 antibody, for the treatment of multiple myeloma, Clin Lymphoma Myeloma Leuk, 13, S180
  2. Usmani, 2019, Preliminary data: phase 1b study of feasibility/safety of isatuximab short duration fixed volume infusion in combination with pomalidomide and dexamethasone for relapsed refractory multiple myeloma, European Hematology Association

Cited by

See all 645

Metadata

Authors
Attal, M., Richardson, P. G., Rajkumar, S. V., San-Miguel, J., Beksac, M., Spicka, I., Leleu, X., Schjesvold, F., Moreau, P., Dimopoulos, M. A., Huang, J. S.-Y., Minarik, J., Cavo, M., Prince, H. M., Macé, S., Corzo, K. P., Campana, F., Le-Guennec, S., Dubin, F., Anderson, K. C., Attal, M., Richardson, P. G., Rajkumar, V., San-Miguel, J., Beksac, M., Spicka, I., Leleu, X., Schjesvold, F., Moreau, P., Dimopoulos, M. A., Huang, J. S.-Y., Minarik, J., Cavo, M., Prince, H. M., Macé, S., Corzo, K. P., Campana, F., Le-Guennec, S., Dubin, F., Anderson, K. C., Harrison, S., Janowski, W., Kerridge, I., Spencer, A., Delforge, M., Fostier, K., Vlummens, P., Wu, K. L., Leblanc, R., Pavic, M., Sebag, M., Hajek, R., Maisnar, V., Pour, L., Gregersen, H., Benbouker, L., Caillot, D., Escoffre-Barbe, M., Facon, T., Frenzel, L., Hulin, C., Karlin, L., Kolb, B., Pegourie, B., Perrot, A., Tiab, M., Vincent, L., Niederwieser, D., Anagnostopoulos, A., Delimpasi, S., Kyrtsonis, M.-C., Symeonidis, A., Illes, A., Mikala, G., Nagy, Z., Bringen, S., Corradini, P., Fabio, C., Lemoli, R., Liberati, A., Nozzoli, C., Zambello, R., Iida, S., Ikeda, T., Iyama, S., Matsumoto, M., Shimazaki, C., Sunami, K., Suzuki, K., Uchiyama, M., Koh, Y., Kim, K., Lee, J. H., Min, C.-K., Blacklock, H., Goodman, H., Neylon, A., Simpson, D., Grosicki, S., Jurczyszyn, A., Walter-Croneck, A., Warzocha, K., Araujo, L., Moreira, C., Doronin, V., Mendeleeva, L., Vorobyev, V., Vranovsky, A., Alegre, A., Gironella, M., Gonzalez Perez, M. S., Montes, C., Ocio, E., Rodriguez, P., Hardling, M., Lauri, B., Wang, M.-C., Yeh, S.-P., Arat, M., Demirkan, F., Gulbas, Z., Besisik, S. K., Karadogan, I., Tuglular, T., Unal, A., Vural, F., Sive, J., Streetly, M., Yong, K., & Tache, J.
Venue
The Lancet
Publisher
Elsevier BV
Published
2019-12
Volume
394
Issue
10214
Pages
2096-2107
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2988984460
Cited by
645
References
31
FWCI
54.24
Type
journal article
Language
en
Update notices
erratum (2019-12-07)
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
Sanofi Pasteur

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. https://app.cochat.ai/papers/10.1016/s0140-6736(19)32556-5
The paper
Attal, M., Richardson, P. G., Rajkumar, S. V., San-Miguel, J., Beksac, M., Spicka, I., Leleu, X., Schjesvold, F., Moreau, P., Dimopoulos, M. A., Huang, J. S.-Y., Minarik, J., Cavo, M., Prince, H. M., Macé, S., Corzo, K. P., Campana, F., Le-Guennec, S., Dubin, F., . . . Tache, J. (2019). Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. The Lancet. https://doi.org/10.1016/s0140-6736(19)32556-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.